Noninvasive diagnostics in NAFLD

Czech version

Authors: K. Dvořák
Authors‘ workplace: IV. interní klinika 1. LF UK a VFN v Praze
Published in: Gastroent Hepatol 2015; 69(2): 110-115
Category: Hepatology: Review article
doi: https://doi.org/10.14735/amgh2015110

Overview

Non-alcoholic fatty liver disease (NAFLD) represents one of the most common chronic liver diseases affecting more than 25% of the population. The majority of patients have simple steatosis, but some develop liver cirrhosis with its complications. In such a prevalent condition there is a need for non-invasive diagnostic methods allowing stratification of patients without liver biopsy. This summary lists the current options of non-invasive diagnostics of NAFLD.

Key words:
non‑alcoholic fatty liver disease – fibrosis – elastography – non‑invasive diagnosis

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
28. 2. 2015

Accepted:
16. 3. 2015

Sources

1. Cholongitas E, Senzolo M, Standish R et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006; 125(5): 710– 721.

2. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128(7): 1898– 1906.

3. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta‑analysis. Hepatology 2011; 54(3): 1082– 1090. doi: 10.1002/ hep.24452.

4. Lee SS, Park SH, Kim HJ et al. Non‑ invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010; 52(4): 579– 585. doi: 10.1016/ j.jhep.2010.01.008.

5. Wong VW, Wong GL, Choi PC et al. Disease progression of non‑alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59(7): 969– 974. doi: 10.1136/ gut.2009.205088.

6. Ekstedt M, Franzén LE, Mathiesen UL et al. Long‑term follow‑up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44(4): 865– 873.

7. Neuschwander‑ Tetri BA, Clark JM, Bass NM et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52(3): 913– 924. doi: 10.1002/ hep.23784.

8. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.

9. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8(3): 521– 533.

10. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37(6): 1286– 1292.

11. Hui AY, Wong VW, Chan HL et al. Histological progression of non‑alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21(4): 407– 413.

12. Haring R, Wallaschofski H, Nauck M et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma‑ glutamyl transpeptidase levels. Hepatology 2009; 50(5): 1403– 1411. doi: 10.1002/ hep.23135.

13. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF‑alpha or adiponectin? Hepatology 2004; 40(1): 46– 54.

14. Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non‑alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27(5): 412– 421.

15. Musso G, Gambino R, Cassader M et al. Meta‑analysis: natural history of non‑alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non‑invasive tests for liver disease severity. Ann Med 2011; 43(8): 617– 649. doi: 10.3109/ 07853890.2010.518623.

16. Dvorak K, Stritesky J, Petrtyl J et al. Use of non‑invasive parameters of non‑alcoholic steatohepatitis and liver fibrosis in daily practice – an exploratory case‑ control study. PLoS One 2014; 9(10): e111551. doi: 10.1371/ journal.pone.0111551.

17. Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30(6): 1356–1362.

18. Machado MV, Cortez‑ Pinto H. Non‑ invasive diagnosis of non‑alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58(5): 1007– 1019. doi: 10.1016/ j.jhep.2012.11.021.

19. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118(6): 1117– 1123.

20. Harrison SA, Oliver D, Arnold HL et al.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57(10): 1441– 1447. doi: 10.1136/ gut.2007.146019.

21. Guha IN, Parkes J, Roderick P et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47(2): 455– 460.

22. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45(4): 846– 854.

23. Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51(2): 454– 462. doi: 10.1002/ hep.23312.

24. Huwart L, Sempoux C, Vicaut E et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135(1): 32– 40. doi: 10.1053/ j.gastro.2008.03.076.